唐少文

发布者：流行病学系发布时间：2017-07-18浏览次数：7940


唐少文，博士，流行病学教授，博士生导师，兼任南京医科大学公共卫生学院流行病学系主任。

本科和硕士毕业于华中科技大学同济医学院，博士毕业于北京大学医学部。主持国家自然科学基金委员会面上项目2项、国家卫计委行业专项子课题1项、其他项目十余项等，以第一作者/通讯作者发表论文七十余篇。参编药物流行病学、循证医学案例版、临床流行病学、现场流行病学、医学研究报告规范解读等专著或教材。先后指导本科生参加第十届中国大学生医学技术技能大赛（预防医学专业赛道金奖）、第四届全国大学生生命科学创新创业大赛（特等奖）、江苏省大学生计算机设计大赛（特等奖）等；先后获得江苏省研究生教育改革成果奖二等奖、南京医科大学教学成果奖特等奖、南京医科大学扬子江奖教金特等奖等。

现为中国药学会药物流行病学专业委员会委员、中国医师协会循证医学专业委员会委员、中国毒理学会临床毒理专业委员会委员、江苏省医学会临床流行病学分会委员、江苏省药学会药物警戒专业委员会委员等。

主要研究方向：药物流行病学、临床研究设计与分析、循证医学与系统评价。

联系方式：南京市江宁区龙眠大道101号，南京医科大学江宁校区至诚楼南422室；邮编211166；邮箱：tomswen@njmu.edu.cn；电话：025-86868224


近三年主要论文：

  1. Wang N, Chen X, Hao Z, Yi H, Tang S*. Association of ABCG2 polymorphisms with susceptibility to anti-tuberculosis drug-induced hepatotoxicity in the Chinese population. Xenobiotica. 2022 May;52(5):527-533. doi: 10.1080/00498254.2022.2093685.

  2. Liu W, Wang N, Zhu J, Zhang M, Lu L, Pan H, He X, Yi H, Tang S*. The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis: A case-control study. Therapie. 2022 May 25:S0040-5957(22)00103-2. doi: 10.1016/j.therap.2022.05.007.

  3. Liu W, Lu L, Pan H, He X, Zhang M, Wang N, Zhu J, Yi H, Tang S*. Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in China. Pharmacogenomics. 2022 May;23(7):431-441. doi: 10.2217/pgs-2022-0015.

  4. Zhang M, Zhu J, Wang N, Liu W, Lu L, Pan H, He X, Yi H, Tang S*. The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury. J Clin Pharm Ther. 2022 Aug;47(8):1276-1283. doi: 10.1111/jcpt.13672.

  5. Zhu J, Liu W, Zhang M, Lu L, Pan H, He X, Wang N, Yang M, Yi H, Tang S*. A validation study of the UGT1A4 rs2011404 variant and the risk of anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population. J Clin Pharm Ther. 2021 Oct; 46(5): 1288-1294. doi: 10.1111/jcpt.13452.

  6. Yang M, Pan H, Chen H, Liu W, Lu L, He X, Yi H, Tang S*. Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study. Infect Genet Evol. 2020 Sep; 83:104349. doi: 10.1016/j.meegid.2020.104349.

  7. Tao B, Yang M, Chen H, Pan H, Liu W, Yi H, Tang S*. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population. J Clin Pharm Ther. 2020 Aug;45(4):638-645. doi: 10.1111/jcpt.13139.

  8. Zhang H, Wu J, Zhang Z, Qian H, Wang Y, Yang M, Cheng Y, Tang S*. Association of Atorvastatin with the Risk of Hepatotoxicity: A Pilot Prescription Sequence Symmetry Analysis. Ther Clin Risk Manag. 2019 Jun 27;15:803-810. doi: 10.2147/TCRM.S204860. eCollection 2019.

  9. Lu L, Tao B, Wei H, Chen H, He X, Pan H, Yang M, Yi H, Tang S*. Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population. J Gene Med. 2019 Jun;21(6):e3096. doi: 10.1002/jgm.3096.

  10. Yang M, Pan H, Lu L, He X, Chen H, Tao B, Liu W, Yi H, Tang S*. The Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study. BMJ Open. 2019 Mar 30;9(3):e027321. doi: 10.1136/bmjopen-2018-027321.

  11. Yang M, Zhang H, Tao B, Pan H, Lu L, Yi H, Tang S*. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: a matched case-control study. J Clin Pharm Ther. 2019 Aug;44(4):534-542. doi: 10.1111/jcpt.12818.

  12. Pan H, Yang M, Lu L, Tao B, He X, Chen H, Yi H, Tang S*. Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population. Pharmacogenet Genomics. 2019 Jun;29(4):84-90. doi: 10.1097/FPC.0000000000000370.